Neuronetics, Inc.

DB:NRC Stock Report

Market Cap: €25.6m

Neuronetics Valuation

Is NRC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NRC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NRC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NRC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NRC?

Key metric: As NRC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NRC. This is calculated by dividing NRC's market cap by their current revenue.
What is NRC's PS Ratio?
PS Ratio0.4x
SalesUS$72.71m
Market CapUS$26.86m

Price to Sales Ratio vs Peers

How does NRC's PS Ratio compare to its peers?

The above table shows the PS ratio for NRC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.8x
AAQ1 aap Implantate
1.9xn/a€22.4m
GME Geratherm Medical
0.9x1.9%€16.5m
AUG Audientes
12.6xn/a€6.9m
PUS PULSION Medical Systems
3.8xn/a€134.4m
NRC Neuronetics
0.4x11.0%€26.9m

Price-To-Sales vs Peers: NRC is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does NRC's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$836.09m
PHH2 Paul Hartmann
0.3xn/aUS$779.09m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
NRC 0.4xIndustry Avg. 3.7xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NRC is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is NRC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NRC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: NRC is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NRC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.81
€2.54
+212.0%
17.7%€2.85€1.90n/a3
Nov ’25€0.93
€3.03
+225.4%
14.1%€3.63€2.72n/a3
Oct ’25€0.66
€3.03
+356.4%
14.1%€3.63€2.72n/a3
Sep ’25€0.75
€3.03
+303.5%
14.1%€3.63€2.72n/a3
Aug ’25€1.68
€6.51
+286.9%
11.7%€7.44€5.58n/a3
Jul ’25€1.62
€6.51
+300.7%
11.7%€7.44€5.58n/a3
Jun ’25€1.70
€6.51
+283.3%
11.7%€7.44€5.58n/a3
May ’25€3.22
€6.42
+99.5%
11.7%€7.34€5.51n/a3
Apr ’25€4.40
€6.42
+46.0%
11.7%€7.34€5.51n/a3
Mar ’25€2.89
€6.10
+111.5%
7.1%€6.41€5.49n/a3
Feb ’25€3.13
€6.10
+95.2%
7.1%€6.41€5.49n/a3
Jan ’25€2.42
€6.06
+150.4%
7.1%€6.36€5.45n/a3
Dec ’24€1.30
€5.60
+331.0%
23.6%€6.54€3.74n/a3
Nov ’24€1.07
€7.64
+615.4%
36.8%€11.46€4.78€0.933
Oct ’24€1.31
€7.29
+456.4%
36.8%€10.93€4.56€0.663
Sep ’24n/a
€7.29
0%
36.8%€10.93€4.56€0.753
Aug ’24€1.62
€8.05
+398.3%
27.2%€11.15€6.50€1.683
Jul ’24€1.79
€8.05
+349.9%
27.2%€11.15€6.50€1.623
Jun ’24€2.30
€7.90
+243.7%
27.2%€10.95€6.38€1.703
May ’24€1.85
€7.91
+328.0%
27.2%€10.95€6.39€3.223
Apr ’24€2.40
€8.21
+241.9%
27.2%€11.37€6.63€4.403
Mar ’24€5.25
€9.10
+73.4%
17.6%€11.30€7.53€2.893
Feb ’24€5.31
€9.10
+71.6%
17.6%€11.30€7.53€3.133
Jan ’24€6.04
€9.10
+50.7%
17.6%€11.30€7.53€2.423
Dec ’23€5.91
€9.93
+68.0%
16.3%€11.91€7.94€1.303
Nov ’23€3.28
€9.51
+189.4%
17.6%€11.80€7.87€1.073

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%